Rapid diagnostic tests that read the immune system
Inflammatix has developed a molecular diagnostic designed to read the patient’s immune system to deliver rapid results, with an initial focus on acute infection and sepsis. Its HostDx tests combine proprietary biomarkers and advanced machine learning.
The company closed a $32 million Series C funding round in January and secured a long-term cost-sharing contract worth up to $72 million from BARDA in November 2019. –SW
Investors include: Khosla Ventures, Northpond Ventures, Think.Health Ventures, Grey Sky Venture Partners, Stanford-StartX Fund